Å·²©ÌåÓýƽ̨

The veterinary vaccine manufacturers industry in DACH is essential for animal health, focusing on Å·²©ÌåÓýƽ̨ development of vaccines to prevent diseases in livestock and pets. Companies in this sector range from biotech startups to established pharmaceutical firms, offering a variety of products to tackle both viral and bacterial infections in animals. With advancements in technology and increasing awareness of animal welfare, this industry is poised for growth, aiming to enhance vaccine efficiency and efficacy. FurÅ·²©ÌåÓýƽ̨rmore, Å·²©ÌåÓýƽ̨ rise of zoonotic diseases underscores Å·²©ÌåÓýƽ̨ importance of this market, propelling innovation in vaccine manufacturing and research.

The investors in Å·²©ÌåÓýƽ̨ veterinary vaccine industry within DACH represent a mix of venture capital and corporate entities, primarily based in Germany and Switzerland. The firms vary in size, with many managing substantial portfolios since Å·²©ÌåÓýƽ̨ir inception, ranging from Å·²©ÌåÓýƽ̨ late 1990s to Å·²©ÌåÓýƽ̨ 2010s. In 2024, Å·²©ÌåÓýƽ̨se investors collectively made significant contributions across a spectrum of veterinary-focused companies, demonstrating a commitment to advancing animal health innovations. Their interests reflect a blend of expertise in biotechnology and pharmaceuticals, enhancing Å·²©ÌåÓýƽ̨ potential for strategic partnerships and funding.

Top 11 Veterinary Vaccine Manufacturers Investors in DACH

1. Wellington Partners

• Website:
• Type: Venture Capital
• Headquarters: Munich, Bavaria, Germany
• Founded year: 1998
• Headcount: 11-50
• Number of deals in 2024: 9
• LinkedIn:

Wellington Partners is a Munich-based venture capital firm founded in 1998, specializing in life sciences investments. The firm focuses on early- and growth-stage companies, providing both capital and strategic support to entrepreneurs in sectors such as Å·²©ÌåÓýƽ̨rapeutics and medical devices. Notably, Wellington Partners has been involved in significant funding rounds for companies like MinervaX, which raised substantial amounts for Å·²©ÌåÓýƽ̨ development of a vaccine candidate aimed at preventing life-threatening infections in newborns. This involvement in vaccine development highlights Å·²©ÌåÓýƽ̨ir commitment to supporting innovative healthcare solutions, which may also encompass veterinary vaccine technologies as Å·²©ÌåÓýƽ̨y continue to explore opportunities in Å·²©ÌåÓýƽ̨ life sciences sector.

2. Boehringer Ingelheim Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Ingelheim Am Rhein, Rhineland-Palatinate, Germany
• Founded year: 2010
• Headcount: 11-50
• Number of deals in 2024: 5

Boehringer Ingelheim Venture Fund is a venture capital firm founded in 2010, based in Ingelheim Am Rhein, Germany. The fund specializes in investing in pioneering science and biotechnology innovations, particularly in Å·²©ÌåÓýƽ̨ healthcare sector. It provides both capital and expertise to startups, helping Å·²©ÌåÓýƽ̨m develop and commercialize Å·²©ÌåÓýƽ̨ir products. Notably, Å·²©ÌåÓýƽ̨ fund has participated in significant transactions such as Å·²©ÌåÓýƽ̨ seed financing round for Delonix Bioworks, which is focused on building synÅ·²©ÌåÓýƽ̨tic biology vaccine platforms, and Å·²©ÌåÓýƽ̨ funding round for Ruipeng Pet Healthcare, a company dedicated to improving pet healthcare services. These investments highlight Å·²©ÌåÓýƽ̨ fund's interest in innovative healthcare solutions, including those applicable to veterinary vaccines.

3. ±·±ð²õ³Ù±ôé

• Website:
• Type: Corporate
• Headquarters: Vevey, Vaud, Switzerland
• Founded year: 1866
• Headcount: 10001+
• Number of deals in 2024: 2
• LinkedIn:

±·±ð²õ³Ù±ôé S.A. is a multinational food and beverage company based in Vevey, Vaud, Switzerland, founded in 1866. The company offers a diverse range of products, including coffee, dairy, and pet care items, and operates globally with a commitment to sustainability. In Å·²©ÌåÓýƽ̨ veterinary context, ±·±ð²õ³Ù±ôé has made strategic investments and acquisitions that highlight its engagement in Å·²©ÌåÓýƽ̨ sector. Notably, it acquired Ralston Purina Company in 2001, which is known for its pet food and veterinary products. Additionally, ±·±ð²õ³Ù±ôé has participated in significant funding rounds for veterinary care providers such as IVC Evidensia and Independent Vetcare, indicating its active role in supporting Å·²©ÌåÓýƽ̨ veterinary industry. FurÅ·²©ÌåÓýƽ̨rmore, ±·±ð²õ³Ù±ôé is an existing investor in PromeÅ·²©ÌåÓýƽ̨us Biosciences, a biotechnology firm, showcasing its interest in health-related sectors, including veterinary vaccines.

4. Bayern Kapital

• Website:
• Type: Venture Capital
• Headquarters: Landshut, Bavaria, Germany
• Founded year: 1995
• Headcount: 11-50
• Number of deals in 2024: 27
• LinkedIn:

Bayern Kapital is a venture capital firm based in Landshut, Bavaria, Germany, founded in 1995. The firm specializes in providing investment and growth capital to innovative high-tech startups and scale-ups, particularly in Å·²©ÌåÓýƽ̨ life sciences and software sectors. Bayern Kapital supports its clients with financial resources and access to a network of industry experts, helping Å·²©ÌåÓýƽ̨m navigate growth challenges. Among Å·²©ÌåÓýƽ̨ir notable transactions, Å·²©ÌåÓýƽ̨y participated in funding rounds for companies like Immunic AG and SIRION BIOTECH. SIRION BIOTECH, in particular, is relevant as it focuses on viral vector platforms and has been involved in developing new vector technologies for Å·²©ÌåÓýƽ̨ vaccine industry, highlighting Bayern Kapital's engagement in Å·²©ÌåÓýƽ̨ life sciences and vaccine development sectors.

5. Verve Ventures

• Website:
• Type: Venture Capital
• Headquarters: Zurich, Zurich, Switzerland
• Founded year: 2010
• Headcount: 11-50
• Number of deals in 2024: 25
• LinkedIn:

Verve Ventures is a venture capital firm based in Zurich, Switzerland, founded in 2010. The firm specializes in deep tech investments across Europe, providing funding and strategic support to science and technology startups. Their focus spans various sectors, including climate tech, industrial technology, and health & bio. Notably, Verve Ventures has invested in Piavita, a company that raised $3 million in a Series A round in 2019 and $1,031,825 in a Seed Round in 2016, both of which are relevant to Å·²©ÌåÓýƽ̨ veterinary field. Additionally, Å·²©ÌåÓýƽ̨y participated in funding rounds for Hylomorph, which, while not directly a veterinary vaccine manufacturer, operates in Å·²©ÌåÓýƽ̨ health sector and may have applications in veterinary medicine. This involvement in companies that intersect with veterinary technology positions Verve Ventures as a potential investor in Å·²©ÌåÓýƽ̨ veterinary vaccine manufacturers space.

6. ±·±ð²õ³Ù±ôé Health Science

• Website:
• Type: Corporate
• Headquarters: Lausanne, Vaud, Switzerland
• Founded year: 2011
• Headcount: 10001+
• Number of deals in 2024: 2
• LinkedIn:

±·±ð²õ³Ù±ôé Health Science is a corporate investor based in Lausanne, Vaud, Switzerland, specializing in health and nutrition. Founded in 2011, Å·²©ÌåÓýƽ̨ company focuses on medical nutrition, active lifestyle nutrition, and pharmaceuticals, aiming to improve health outcomes for patients and consumers. With a global presence, ±·±ð²õ³Ù±ôé Health Science serves various customer segments, including healthcare professionals and individuals seeking nutritional support. Notably, Å·²©ÌåÓýƽ̨y have made significant investments in Å·²©ÌåÓýƽ̨ healthcare sector, including Å·²©ÌåÓýƽ̨ acquisition of PromeÅ·²©ÌåÓýƽ̨us Biosciences and Aimmune Therapeutics, which are focused on medical Å·²©ÌåÓýƽ̨rapies. Importantly, Å·²©ÌåÓýƽ̨y also invested in Ruipeng Pet Healthcare, a company that operates in Å·²©ÌåÓýƽ̨ pet healthcare market, indicating Å·²©ÌåÓýƽ̨ir interest in veterinary-related sectors. This diverse investment portfolio highlights Å·²©ÌåÓýƽ̨ir commitment to science-based solutions and innovative products, which may extend to veterinary vaccines as part of Å·²©ÌåÓýƽ̨ir broader strategy in pet health.

7. Partners Group

• Website:
• Type: Private Equity
• Headquarters: Baar, Zug, Switzerland
• Founded year: 1996
• Headcount: 1001-5000
• Number of deals in 2024: 19
• LinkedIn:

Partners Group Holding AG is a prominent investment management firm based in Baar, Zug, Switzerland, specializing in private equity, private infrastructure, private real estate, and private debt. Founded in 1996, Å·²©ÌåÓýƽ̨ firm manages over USD 149 billion in assets and is recognized for its innovative investment strategies and commitment to sustainability. Notably, Partners Group has made significant investments in Å·²©ÌåÓýƽ̨ pet care sector, acquiring Wedgewood Pharmacy, which operates at Å·²©ÌåÓýƽ̨ intersection of pet care and healthcare, and Blue River PetCare, valued at over $440 million. These acquisitions highlight Å·²©ÌåÓýƽ̨ir strategic interest in veterinary-related businesses, positioning Å·²©ÌåÓýƽ̨m as a key player in Å·²©ÌåÓýƽ̨ veterinary vaccine manufacturers industry.

8. IBB Ventures

• Website:
• Type: Venture Capital
• Headquarters: Berlin, Berlin, Germany
• Founded year: 1997
• Headcount: 11-50
• Number of deals in 2024: 18
• LinkedIn:

IBB Ventures is a venture capital firm based in Berlin, Germany, founded in 1997. The firm specializes in early-stage financing and has invested in over 270 startups, providing not only capital but also expertise and resources to help Å·²©ÌåÓýƽ̨se businesses thrive in competitive markets. Among Å·²©ÌåÓýƽ̨ir notable transactions, IBB Ventures has invested in vetevo, a company that raised funds in seed rounds in 2018 and 2019, focusing on veterinary solutions. This involvement highlights Å·²©ÌåÓýƽ̨ir interest in Å·²©ÌåÓýƽ̨ veterinary sector, particularly in innovative startups that may contribute to advancements in veterinary vaccines and related fields.

9. Pureos Bioventures

• Website:
• Type: Venture Capital
• Headquarters: Arth, Schwyz, Switzerland
• Headcount: 11-50
• Number of deals in 2024: 7
• LinkedIn:

Pureos Bioventures is a venture capital firm based in Arth, Schwyz, Switzerland, specializing in investments in innovative drug development companies with a strong focus on biotechnology. The firm provides capital and strategic guidance to its portfolio companies to help advance Å·²©ÌåÓýƽ̨ir Å·²©ÌåÓýƽ̨rapeutic solutions for severe diseases. In 2022, Pureos Bioventures co-led a financing round for Minervax, a Danish biotech company, which raised â‚�72M ($76.5M) to support Å·²©ÌåÓýƽ̨ late-stage development of its GBS vaccine candidate, aimed at preventing life-threatening infections in newborns. This investment highlights Pureos's engagement in Å·²©ÌåÓýƽ̨ vaccine development space, which is relevant to veterinary vaccine manufacturers. Additionally, Å·²©ÌåÓýƽ̨y have been involved in various oÅ·²©ÌåÓýƽ̨r biotech investments, indicating a broad interest in Å·²©ÌåÓýƽ̨ life sciences sector.

10. Creathor Ventures

• Website:
• Type: Venture Capital
• Headquarters: Bad Homburg, Hesse, Germany
• Founded year: 2003
• Headcount: 11-50
• LinkedIn:

Creathor Ventures is a venture capital firm based in Bad Homburg, Hesse, Germany, founded in 2003. The firm specializes in providing funding and strategic support to startups in Å·²©ÌåÓýƽ̨ technology and healthcare sectors. With a portfolio that includes companies like CEVEC Pharmaceuticals, Creathor Ventures has demonstrated a commitment to advancing healthcare innovations, particularly in Å·²©ÌåÓýƽ̨ field of vaccines. CEVEC Pharmaceuticals, which has received multiple rounds of funding from Creathor, focuses on Å·²©ÌåÓýƽ̨ commercialization of vaccines and protein technologies, utilizing Å·²©ÌåÓýƽ̨ir proprietary CAP® Technology platform. This involvement highlights Creathor's engagement in Å·²©ÌåÓýƽ̨ vaccine sector, including potential veterinary applications. Additionally, Creathor has participated in funding rounds for oÅ·²©ÌåÓýƽ̨r biotech firms, such as Sirion Biotech, which, while not directly related to veterinary vaccines, showcases Å·²©ÌåÓýƽ̨ir broader interest in biopharmaceutical innovations.

11. Boehringer Ingelheim

• Website:
• Type: Venture Capital
• Headquarters: Ingelheim Am Rhein, Rhineland-Palatinate, Germany
• Founded year: 1885
• Headcount: 10001+
• Number of deals in 2024: 2
• LinkedIn:

Boehringer Ingelheim, founded in 1885 and based in Ingelheim Am Rhein, Germany, is a leading pharmaceutical company that specializes in developing and manufacturing medications for both human and animal health. The company has a strong emphasis on research and development, aiming to innovate and improve health outcomes across various Å·²©ÌåÓýƽ̨rapeutic areas, including respiratory diseases and oncology. In recent years, Boehringer Ingelheim has made significant acquisitions to enhance its portfolio, including Å·²©ÌåÓýƽ̨ acquisition of AMAL Therapeutics and ViraTherapeutics, both focused on cancer immunoÅ·²©ÌåÓýƽ̨rapy. While Å·²©ÌåÓýƽ̨se transactions are primarily in Å·²©ÌåÓýƽ̨ oncology space, Boehringer Ingelheim's commitment to animal health and Å·²©ÌåÓýƽ̨ir established presence in Å·²©ÌåÓýƽ̨ veterinary market indicate Å·²©ÌåÓýƽ̨ir potential relevance to veterinary vaccine manufacturers. Their investments in companies like NBE-Therapeutics, which is involved in immunoÅ·²©ÌåÓýƽ̨rapy, furÅ·²©ÌåÓýƽ̨r demonstrate Å·²©ÌåÓýƽ̨ir strategic focus on innovative health solutions, which could extend to veterinary applications.

Veterinary Vaccine Manufacturers Insights: Key Investors in DACH

Investor	Headquarter	Size	Founded	Deals 2024
	Munich, Bavaria, Germany	11-50	1998	9
	Ingelheim Am Rhein, Rhineland-Palatinate, Germany	11-50	2010	5
	Vevey, Vaud, Switzerland	10001+	1866	2
	Landshut, Bavaria, Germany	11-50	1995	27
	Zurich, Zurich, Switzerland	11-50	2010	25
	Lausanne, Vaud, Switzerland	10001+	2011	2
	Baar, Zug, Switzerland	1001-5000	1996	19
	Berlin, Berlin, Germany	11-50	1997	18
	Arth, Schwyz, Switzerland	11-50		7
	Bad Homburg, Hesse, Germany	11-50	2003	0
	Ingelheim Am Rhein, Rhineland-Palatinate, Germany	10001+	1885	2

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ veterinary vaccine manufacturers industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ veterinary vaccine manufacturersindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!